Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Inks Deal to Provide Liquid Biopsies Through PPO FedMed

NEW YORK (GenomeWeb) – Trovagene today announced it has signed an agreement to provide its Precision Cancer Monitoring tests and services to the national preferred provider organization FedMed.

Under the terms of the agreement, Trovagene will be covered as a participating laboratory testing provider for FedMed clients, which include major health insurers such as Aetna, Cigna and Humana. FedMed's network includes over 550,000 in-network physicians nationwide, the firm said in a statement.

Financial details of the agreement weren't disclosed.

San Diego-based Trovagene's tests can detect and monitor circulating tumor DNA in urine.

"We're very pleased with the positive response we are receiving from national provider networks, validating our decision to design the PCM platform to report on clinically actionable cancer genes that can translate into clear use scenarios and better reimbursement outcomes," Trovagene Chief Commercial Officer Matt Posard said in a statement.

Last month, Trovagene signed a deal to offer its PCM tests and services with America's Choice Provider Network.

"We remain committed to creating a strong foundation of studies demonstrating the multiple clinical utilities of our technology, which we believe will broaden health insurance coverage and patient access this year," Posard said.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.